Correlation between antibiotic use and changes in susceptibility patterns of Pseudomonas aeruginosa in a medical-surgical intensive care unit

Indian Journal of Critical Care Medicine

Volumn 12, Issue 1, 2008, Pages 18-23

  Kallel, Hatem ^a   Mahjoubi, Fouzia ^a   Dammak, Hassen ^a   Bahloul, Mabrouk ^a   Hamida, Chokri ^a   Chelly, Hedi ^a   Rekik, Noureddine ^a   Hammami, Adnène ^a   Bouaziz, Mounir ^a  

^a HABIB BOURGUIBA HOSPITAL   (Tunisia)

Author keywords

Ciprofloxacin; Imipenem; P. aeruginosa; Resistance; Use

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; DRUG UTILIZATION; HUMAN; INTENSIVE CARE UNIT; NONHUMAN; POLICY; PRESCRIPTION; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY;

EID: 44849143679     PISSN: 09725229     EISSN: 1998359X     Source Type: Journal    
DOI: 10.4103/0972-5229.40945     Document Type: Article

References (22)

1. Spencer RC. Predominant pathogens found in the European prevalence of infection in intensive care study. Eur J Clin Microbiol Infect Dis 1996;5:281-5.
2. Fluit AC, Verhoef J, Schmitz FJ; European SENTRY Participants. Frequency of isolation and antimicrobial resistance of gram-negative and gram-positive bacteria from patients in intensive care units of 25 European university hospitals participating in the European arm of the SENTRY Antimicrobial Surveillance Program 1997-1998. Eur J Clin Microbiol Infect Dis 2001;20:617-25.
3. Gunseren F, Mamikoglu L, Ozturk S, Yucesoy M, Biberoglu K, Yulug N, et al. A surveillance study of antimicrobial resistance of gram-negative bacteria isolated from intensive care units in eight hospitals in Turkey. J Antimicrob Chemother 1999;43:373-8.
4. Kallel H, Bahoul M, Ksibi H, Dammak H, Chelly H, Hamida CB, et al. Prevalence of hospital-acquired infection in a Tunisian hospital. J Hosp Infect 2005;59:343-7.
5. Gaynes RP, Culver DH. Resistance to imipenem among selected gram-negative bacilli in the United States. Infect Control Hosp Epidemiol 1992;13:10-4.
6. Quinn JP. Imipenem resistance among gram-negative bacilli. Eur J Clin Microbiol Infect Dis 19941;3:203-4.
7. El Amari EB, Chamot E, Auckenthaler R, Pechere JC, Van Delden C. Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin Infect Dis 2001;33:1859-64.
8. Paramythiotou E, Lucet JC, Timsit JF, Vanjak D, Paugam-Burtz C, Trouillet JL, et al. Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: Role of antibiotics with antipseudomonal activity. Clin Infect Dis 2004;38:670-7.
9. Lepper PM, Grusa E, Reichl H, Hogel J, Trautmann M. Consumption of imipenem correlates with beta-lactam resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2002;46:2920-5.
10. Mohr JF, Jones A, Ostrosky-Zeichner L, Wanger A, Tillotson G. Associations between antibiotic use and changes in susceptibility patterns of Pseudomonas aeruginosa in a private, university-affiliated teaching hospital: An 8-year-experience: 1995-2002. Int J Antimicrob Agents 2004;24:346-51.
11. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: Comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999;43:1379-82.
12. Paterson DL. "Collateral damage" from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis 2004;38:S341-5.
13. th ed. ASM Press: Washington, DC; 1999. p. 517-25.
14. th ed. ASM Press: Washington, DC; 1999. p. 1526-43.
15. Spencer RC. Predominant pathogens found in the European Prevalence of Infection in Intensive Care Study. Eur J Clin Microbiol Infect Dis 1996;15:281-5.
16. Loeffler JM, Garbino J, Lew D, Harbarth S, Rohner P. Antibiotic consumption, bacterial resistance and their correlation in a Swiss university hospital and its adult intensive care units. Scand J Infect Dis 2003;35:843-50.
17. Troillet N, Samore MH, Carmeli Y. Imipenem-resistant Pseudomonas aeruginosa: Risk factors and antibiotic susceptibility patterns. Clin Infect Dis 1997;25:1094-8.
18. Landman D, Quale JM, Mayorga D, Adedeji A, Vangala K, Ravishankar J, et al. Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: The preantibiotic era has returned. Arch Intern Med 2002;162:1515-20.
19. Falagas ME, Kasiakou SK. Colistin: The revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005;40:1333-41.
20. Kallel H, Bahloul M, Hergafi L, Akrout M, Ketata W, Chelly H, et al. Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU. Int J Antimicrob Agents 2006;28:366-9.
21. Mutnick AH, Rhomberg PR, Sader HS, Jones RN. Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001). J Antimicrob Chemother 2004;53:290-6.
22. Kallel H, Hedi C, Maaloul I, Bahloul M, Ksibi H, Khemakhem B, et al. Evaluation of the antibiotics consumption in a Tunisian university hospital. Tunis Med 2005;83:110-3.